<DOC>
	<DOCNO>NCT02064010</DOCNO>
	<brief_summary>This Phase 2 study design evaluate efficacy safety SNC-102 subject drug-induced Tardive Dyskinesia ( TD ) . To ensure adequate evaluation SNC-102 , randomize , double-blind , parallel-group , placebo-controlled trial design . Two dosing level SNC-102 employ evaluate propose dose range . A target enrollment 90 subject drug-induced TD provide sufficient data ass efficacy safety profile SNC-102 target population .</brief_summary>
	<brief_title>A Phase 2 Trial Evaluating SNC-102 Drug-Induced Tardive Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>1 . Males females 1875 year age . 2 . Diagnosis , least 3 month prior Screening Visit , druginduced TD 1 . AIMS ≥3 ( moderate worse ) ≥1 body area , AIMS = 2 ( mild ) ≥2 body area ; 2 . &gt; 3 month exposure antipsychotic drug metoclopramide ; 3 . Other cause dyskinesia rule . 3 . AIMS score confirm Screening Visit Principal Investigator Trial Reading Center , Baseline Visit least 1 week later Principal Investigator . 4 . If use antipsychotic medication metoclopramide , dose stable least 60 day prior Baseline Visit expect remain stable course trial . 5 . If use opioid medication , dose stable least 14 day prior Baseline Visit expect remain stable course trial . 6 . If use vitamin dietary supplement , dose type stable least 14 day prior Baseline Visit expect remain stable course trial . 7 . If use alcohol , willingness limit intake 2 drinks/day course participation trial , abstain least 12 hour prior assessment visit . 1 . Unstable psychiatric status , indicate change psychotropic medication ( unless approve Sponsor ) , hospitalization , within 60 day prior Screening Visit . 2 . Active drug alcohol dependence abuse . 3 . Current use cocaine , amphetamine , phencyclidine ( PCP ) , ketamine , document either history urinary drug screen Screening Baseline Visits . Drugs use treat attention deficithyperactivity disorder allow stable least 14 day prior Baseline Visit expect remain stable course trial . 4 . Risk significant medication nonadherence , base judgment Principal Investigator . 5 . Neurologic psychiatric disorder could interfere attribution observe involuntary movement TD , primary movement disorder unrelated medication . 6 . History neuroleptic malignant syndrome . 7 . Significant risk , judgment Principal Investigator , suicidal violent behavior . 8 . Receipt new medication treatment TD within 4 week prior Baseline Visit anticipate participate trial . 9 . Initiation oral contraceptive medication , change dose , within 30 day prior Screening Visit , anticipate participate trial . 10 . Gastrointestinal disease shortbowel malabsorption syndrome , judgment Principal Investigator , could interfere absorption orallyadministered medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>